Cardiol Therapeutics Inc. (FRA:CT9)

Germany flag Germany · Delayed Price · Currency is EUR
0.7760
-0.0090 (-1.15%)
At close: Dec 19, 2025
-38.02%
Market Cap86.95M
Revenue (ttm)n/a
Net Income (ttm)-21.28M
Shares Outn/a
EPS (ttm)-0.26
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume80
Average Volume209
Open0.7950
Previous Close0.7850
Day's Range0.7760 - 0.7950
52-Week Range0.6000 - 1.4420
Betan/a
RSI44.51
Earnings DateMar 27, 2026

About Cardiol Therapeutics

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical develop... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2017
Employees 18
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol CT9
Full Company Profile

Financial Performance

Financial numbers in CAD Financial Statements

News

There is no news available yet.